The Dragon City Pharmacy has become a cult favorite for Chinese visitors to Hong Kong, selling everything from medicines to mascara. Even so, the owners of this mom-and-pop business were bewildered when copycat drug stores bearing its brand began popping up across the city.
In recent years, outlets named after the 60-year-old store — but with no affiliation — have opened up alongside a slew of other tiny pharmacies in Hong Kong’s prime tourist districts, minutes away from the Louis Vuitton and Chanel stores that dot the town. Often decorated in rainbow neon lights, these smaller outlets advertise sales of tax-free medicines.
Their line-up includes muscle rubs, painkillers, aphrodisiacs and traditional Chinese medicine. However, if you ask quietly, many will also sell you something else: cancer and hepatitis C drugs — no prescription necessary.
Photo: bloomberg
For years, Hong Kong was known as the place where Chinese shoppers picked up the newest fashions from luxury retailers like Gucci and Prada. Now, prescription drugs are also an attraction.
Treatments such as Gilead Sciences Inc’s Sovaldi for hepatitis C and Roche Holding AG’s breast-cancer treatment Herceptin are either unavailable or more expensive in China. Many visitors from the mainland also prefer to buy their medicines in Hong Kong because they believe it is likely to be better quality.
“Every time I’m here for one of my shopping trips someone or the other will ask me to bring them back some medicine. We all know Hong Kong has better-quality products,” a 52-year-old woman surnamed Chen said in the Tsim Sha Tsui tourist district, where she was stocking up on makeup and shampoo.
The most urgent item on her shopping list was the liver cancer medicine Nexavar, although she did not have a prescription. She planned to stroll around and ask for the drug made by Bayer AG in the dozens of drug stores in the area. Chen had bought similar medicines before and it was pretty easy, she said, holding a Rhinestone encrusted iPhone in one hand while packing a wheeled suitcase with her purchases. Also on her list: a Rolex watch.
Chinese shoppers like Chen are traveling across the border in search of cheaper drugs as changing lifestyles have put China in the grips of a cancer epidemic.
The WHO says that 3 million new cases are added each year. Estimates of China’s hepatitis C population range from 13 million to 44 million: among the highest in the world.
The cross-border trade in Hong Kong also highlights the problems facing China’s prescription drug market, which by the estimates of research firm Frost & Sullivan had total sales of 1 trillion yuan (US$157 billion) last year. That is expected to double by 2019.
Even as regulators apply pressure to lower costs, mainland Chinese patients pay some of the highest prices for treatments worldwide.
Drug supply chains are complex, and Frost & Sullivan consultant Neil Wang estimates there is a 5 to 7 percent markup at various levels of the distribution system that drives up prices. Also, taxes on imported medicines can add up to 17 percent in China, according to Wang, while Hong Kong does not tax drug imports.
Most Chinese rely on government insurance, and that coverage is often not enough. While China has signaled it would like to reform its insurance laws, millions are still left scrambling for access to life-saving treatments. Meanwhile, a lengthy approval process for new drugs and their patents has stalled the entry of some of the newest blockbusters from overseas.
Neither Gilead’s Sovaldi nor AbbVie Inc’s Viekira Pak — two treatments that can cure hep C — are approved for sale as yet in China, even though the companies have made registration applications. Both drugs are approved for sale in Hong Kong, which has a separate approval process.
Calls to the Chinese Ministry of Health and Food and Drug Administration were not answered.
After a series of scandals around food safety, including milk tainted with melamine that caused deaths in 2008, many Chinese have greater trust in products bought overseas. So, even while Hong Kong retail sales have slumped, these pharmaceutical sales are helping some of the tiny stores in the tourist district stay afloat.
This is how it works: A customer goes in and asks for a certain drug — perhaps with a photograph of the bottle. Store workers look up the treatment, call around, look at inventory and provide a quote. They ask for half or full payment. Many only take cash, while a few accept credit cards.
Bloomberg visited 40 pharmacies in Hong Kong and found several willing to dispense treatments such as Viekira Pak, Herceptin, Sovaldi, Bayer’s Nexavar for liver cancer, and Novartis AG’s Glivec for leukemia, without a prescription.
Some quoted prices that were cheaper than those listed by pharmacies on the mainland; the charges for some treatments not available in China tracked those in the US. One pharmacy offered to sell Sovaldi for about US$2,800, a fraction of the US price of US$84,000, which rendered the merchandise suspect.
The real Dragon City Pharmacy says it will only provide drugs to those with a Hong Kong prescription. This was corroborated by customers who had just visited and asked for treatments.
The original Dragon City also says it has had complaints of customers mistakenly going to copycat branches and ending up paying too much.
“All we have is our brand and we feel it’s being tarnished,” said Dragon City manager Kwong, who asked that only her last name be used. “But even if we complain, one after another keeps popping up.”
William Chui, president of the city’s Society of Hospital Pharmacists of Hong Kong, estimates that 90 percent of cancer drug sales at Hong Kong drugstores are to mainland tourists, since most local patients can get their supply through hospitals or their doctors (in China and Hong Kong, physicians can dispense as well as prescribe medicines).
“How can they survive and pay the salary of a pharmacist and the rental cost?” said Chui, referring to the mom-and-pop stores opening up in some of the city’s high-priced neighborhoods. “You think they can get by just selling toilet rolls, formula milk powder, shampoo? Of course not.”
On a smoggy Friday in Hong Kong, one mainland Chinese woman surnamed Li said she had just put a down payment on Herceptin for a cousin from Hebei Province.
The drug was costing her HK$20,000 (US$2,500), and she could pick it up the next day. The price they quoted her is about 30 percent lower than in some parts of China.
“When we found out she had cancer, I rescheduled my trip and came here earlier,” she said, standing on Nathan Road. “This is life or death, so of course we will do all that it takes to get the best treatment.”
Cairo’s new monorail slices across the city skyline, running above the familiar chaos of blaring horns and aging buses’ exhaust fumes that mark rush hour below. The US$4.5 billion monorail, opened this month, is among Egypt’s most prominent new transport projects, part of a debt-funded infrastructure drive criticized for sapping state finances while bringing limited benefits to most of the country’s 109 million people. “It feels like you’re in a different country,” said Ramy Sayed, a restaurant manager, aboard a driverless Innovia 300 train. “No noise, no traffic, we’re not used to this.” The eastern line runs 56km from the bustling middle-class
Starlux Airlines Co (星宇航空) today unveiled a long-haul network expansion plan at a shareholders’ meeting in Taipei, including direct flights to Barcelona, Spain, and Zurich, Switzerland, as well as a service connecting Taipei, Sydney and New Zealand. Starlux is to become the first Taiwanese carrier to offer non-stop services to the two European cities, while the inaugural oceanic route is expected to expand transit opportunities within the Australia-New Zealand market, Starlux said. Flight services to Chicago, Dallas, Washington and New York are under evaluation, the airline added. Prior to the shareholders’ meeting, the airline earlier this year announced that it would be
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
RSS